To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma (NCT04443049) (2021)

Government Record · Institute of Liver and Biliary Sciences, India (sponsor) · October 5, 2021

Institute of Liver et al., 2021-10-05: Registry record for an Indian trial adding mebendazole 100 mg twice daily to lenvatinib in cirrhotic patients with advanced hepatocellular carcinoma. It lists 170 planned participants and an unknown status.

Mebendazole will be given at dose of 100 mg orally twice a day (BD) daily

n/a

Institute of Liver et al., 2021-10-05: Registry record for an Indian trial adding mebendazole 100 mg twice daily to lenvatinib in cirrhotic patients with advanced hepatocellular carcinoma. It lists 170 planned participants and an unknown status. Record field quoted from the arm description; registry record. Study type: phase not applicable (registry lists NA), randomized, open-label. N=170 estimated. Country: India. Dose: mebendazole 100 mg orally twice daily; lenvatinib per standard dosing. Sponsor: Institute of Liver and Biliary Sciences. Status: UNKNOWN (last known recruiting); start 2020-07-10; estimated completion 2022-06-19. hasResults=false. Comparator: lenvatinib alone. No published results located. Registry entry; no results posted.